MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC

Abstract Resistance to androgen receptor (AR) inhibitors, including enzalutamide (Enz), as well as bone metastasis, are major challenges for castration-resistant prostate cancer (CRPC) treatment. In this study, we identified that miR26a can restore Enz sensitivity and inhibit bone metastatic CRPC. T...

Full description

Bibliographic Details
Main Authors: Yuanyuan Wang, Jiyuan Chen, Luyao Gong, Yunxia Wang, Aino Siltari, Yan-Ru Lou, Teemu J. Murtola, Shen Gao, Yuan Gao
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Nanobiotechnology
Subjects:
Enzalutamide
Drug resistance
Nanoparticles
Castration-resistant prostate cancer (CRPC)
Bone metastatic CRPC
Online Access:https://doi.org/10.1186/s12951-024-02438-z

Internet

https://doi.org/10.1186/s12951-024-02438-z

Similar Items